Timothy Coughlin
CIK 1376043 · Chief Financial Officer · last filed 2026-06-16
Timothy Coughlin is a Chief Financial Officer who has filed 86 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for TVTX, was dated Jun 16, 2026. Across all open-market trades the lifetime net is −$13.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $30.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$30.29M
8
86
-$13.49M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | Director | 66,250 | $55.91 | $3.70M | -$1.27M | 9 | 2026-06-16 |
| VIR | Director | 8,000 | $8.85 | $70.8K | $0 | 1 | 2026-06-10 |
| ADCT | Director | 72,400 | $1.11 | $80.4K | $0 | 2 | 2026-06-03 |
| ATYR | Director | — | $0.49 | — | $0 | 1 | 2026-05-13 |
| LIFE | Director | 56,000 | $18.80 | $1.05M | $87.5K | 12 | 2025-05-02 |
| FATE | Director | 66,282 | $2.32 | $153.8K | $117.2K | 12 | 2024-06-11 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 32,000 | — | — | $0 | 6 | 2020-05-19 |
| NBIX | Chief Financial Officer | 137,961 | $182.83 | $25.22M | -$12.42M | 40 | 2017-02-08 |
Recent Filings
86 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-16 | TVTX | Mixed | — | -$235.5K | EDGAR |
| 2026-06-12 | TVTX | Notice (144) | −10,000 | -$500.4K | EDGAR |
| 2026-06-10 | VIR | Grant (A) | +16,000 | $0 | EDGAR |
| 2026-06-03 | ADCT | Mixed | +32,400 | -$38.8K | EDGAR |
| 2026-05-21 | TVTX | Grant (A) | +4,000 | $0 | EDGAR |
| 2026-05-19 | TVTX | Sell (S) | −3,250 | -$141.3K | EDGAR |
| 2026-05-15 | TVTX | Notice (144) | −3,250 | -$141.2K | EDGAR |
| 2026-05-13 | ATYR | Grant (A) | — | $0 | EDGAR |
| 2025-11-04 | TVTX | Mixed | — | -$325.6K | EDGAR |
| 2025-10-31 | TVTX | Notice (144) | −18,000 | -$629.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.